Please assess the completion status of the following clinical trial:

Trial Title: Morphine Versus Methadone As First Line Strong Opioid for Cancer Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient has pain caused by advanced cancer (local recurrence or metastatic disease)~2. Patient reporting average pain score for the last 24 hours is \>/= 4 on a numerical scale from 0 to 10 (0= no pain, 10=the worst possible pain).~3. Patient is receiving mild opioids (e.g. propoxyphene, codeine, tramadol, hydrocodone), mixed agonist/antagonist (e.g. buprenorphine) or no opioids.~4. Patient requires initiation of strong opioid for cancer pain.~5. Patient has the ability to receive morphine or methadone orally.~6. Patient has no known allergy or severe toxicity to morphine or morphine-like drugs (e.g. hydromorphone, oxycodone, oxymorphone, codeine, hydrocodone, levorphanol), or methadone or methadone-like drug (e.g. propoxyphene).~7. Patient has normal cognition defined as normal state of arousal and absence of obvious clinical findings of confusion, memory or concentration deficit.~8. Patient has normal renal function (creatinine and blood urea nitrogen (BUN) within normal limits) \</= 4 weeks of study entry.~9. Patient's performance status (ECOG) is 3 or less.~10. Patient is willing to sign written informed consent.~11. Patient is 18 years of age or older.~12. Patient is able to return to clinic for evaluation by physician day 8 , 15 , 29, 57 and 85 ( +/- 3 days) during study period.~Exclusion Criteria:~1. Patient has concurrent strong opioid for cancer pain, such as morphine, hydromorphone, oxycodone, meperidine, fentanyl, oral transmucosal fentanyl citrate (OTFC), sufentanil, methadone, levorphanol, transdermal fentanyl.~2. Patient is receiving radiation therapy for pain control.~3. Patient is receiving drugs that interacting with methadone, such as (delavirdine, fluconazole, fluvoxamine, bravavir, amprenavir, efavirenz, lopinavir, nelfinavir, nevirapine, carbamazepine, dexamethasone (Patients receiving short term chemotherapy-related doses are permitted) , phenytoin, rifampin, or grapefruit,).~4. Patients are determined incapable of completing the evaluation forms.~5. Severe hypotension, acute or severe asthma, paralytic ileus, gastrointestinal obstruction, severe respiratory depression.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Morphine Capsule (Type: ACTIVE_COMPARATOR): Morphine 15 mg slow release orally every 12 hours + additional doses as needed
- Methadone Capsule (Type: ACTIVE_COMPARATOR): Methadone 5 mg orally every 12 hours + additional as needed doses up to 40-50 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).